Neuren Pharmaceuticals
Update in progressNEU.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on therapies for neurological disorders. It develops DAYBUE (trofinetide) for Rett syndrome in adults and children aged 2 years and older, with a Phase 2 program for Fragile X syndrome. NNZ‑2591 has completed Phase 2 for Phelan–McDermid syndrome and is in Phase 2 for Angelman and Pitt‑Hopkins syndromes, with preclinical work for Prader‑Willi syndrome, Hypoxic Ischemic Encephalopathy and SYNGAP1. Founded in 2001, it is based in Hawthorn East, Australia.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketASX (ASX)
- LocationAustralia
- CEOMr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.
- Founded2001
- Websitewww.neurenpharma.com
Identifiers
- ISINNZNEUE0001S8